切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2016, Vol. 05 ›› Issue (04) : 249 -253. doi: 10.3877/cma.j.issn.2095-3232.2016.04.011

所属专题： 文献；

临床研究

肝细胞癌合并门静脉癌栓患者手术治疗预后影响因素
崔云龙1, 李强1, 张倜1, 孔大陆1, 李慧锴1, 武强1, 宋天强1,†()   
  1. 1. 300060　天津医科大学附属肿瘤医院肝胆肿瘤科　天津市肿瘤防治重点实验室
  • 收稿日期:2016-04-28 出版日期:2016-08-10
  • 通信作者: 宋天强

Influencing factors for prognosis of patients with hepatocellular carcinoma complicated with portal vein tumor thrombus after surgical treatment

Yunlong Cui1, Qiang Li1, Ti Zhang1, Dalu Kong1, Huikai Li1, Qiang Wu1, Tianqiang Song1,†()   

  1. 1. Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjing 300060, China
  • Received:2016-04-28 Published:2016-08-10
  • Corresponding author: Tianqiang Song
  • About author:
    Corresponding author: Song Tianqiang, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

崔云龙, 李强, 张倜, 孔大陆, 李慧锴, 武强, 宋天强. 肝细胞癌合并门静脉癌栓患者手术治疗预后影响因素[J/OL]. 中华肝脏外科手术学电子杂志, 2016, 05(04): 249-253.

Yunlong Cui, Qiang Li, Ti Zhang, Dalu Kong, Huikai Li, Qiang Wu, Tianqiang Song. Influencing factors for prognosis of patients with hepatocellular carcinoma complicated with portal vein tumor thrombus after surgical treatment[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2016, 05(04): 249-253.

目的

探讨肝细胞癌（肝癌）合并门静脉癌栓患者手术治疗后的预后影响因素。

方法

回顾性分析2010年6月至2013年6月在天津医科大学附属肿瘤医院行手术治疗的32例肝癌合并门静脉癌栓患者临床资料。所有患者均签署知情同意书，符合医学伦理学规定。其中男25例，女7例；年龄35～75岁，中位年龄66岁。观察患者1、2、3年累积生存率和无复发生存率，并分析影响患者总体生存和无复发生存的独立危险因素。生存分析采用Kaplan-Meier法和Log-rank检验。多因素分析采用Cox比例风险回归模型。

结果

患者中位生存期为18个月，1、2、3年累积生存率分别为62.5%、43.5%、33.5%。患者中位无复发生存期为6个月，1、2、3年无复发生存率为37.5%、18.2%、10.9%。多因素分析显示，癌栓分级（RR=4.632，95%CI：1.528～14.039；P<0.05）、手术方式（RR=4.928，95%CI：1.233～19.696；P<0.05）和复发后采取措施（RR=21.069，95%CI：3.529～125.806；P<0.05）是患者术后总体生存率的独立影响因素；采取预防复发措施是患者术后无复发生存率的独立影响因素（RR=4.486，95%CI：1.807～11.138；P<0.05）。

结论

手术治疗对于肝癌合并门静脉癌栓有一定的临床应用价值，癌栓分级、手术方式和复发后采取措施是患者术后总体生存的独立影响因素，而采取预防复发措施是患者术后无复发生存的独立影响因素。

关键词: 癌，肝细胞, 肿瘤细胞，循环, 肝切除术, 存活率
Objective

To investigate the influencing factors for the prognosis of patients with hepatocellular carcinoma (HCC) complicated with portal vein tumor thrombus (PVTT) after surgical treatment.

Methods

Clinical data of 32 patients with HCC and PVTT who underwent surgical treatments in Tianjin Medical University Cancer Institute and Hospital between June 2010 and June 2013 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. There were 25 males and 7 females, aged from 35 to 75 years old with a median age of 66 years old. The 1-, 2-, 3-year cumulative survival and recurrence-free survival of the patients were observed, and independent risk factors for the overall and recurrence-free survival were analyzed. Survival analysis was conducted using Kaplan-Meier method and Log-rank test. Multivariate analysis was conducted using Cox proportional hazard regression model.

Results

The median survival time was 18 months, and the 1-, 2- , 3-year cumulative survival was respectively 62.5%, 43.5% and 33.5%. The median recurrence-free survival time was 6 months, and the 1-, 2-, 3-year recurrence-free survival was respectively 37.5%, 18.2% and 10.9%. Multivariate analysis revealed that PVTT staging (RR=4.632, 95%CI: 1.528-14.039; P<0.05), surgical procedure (RR=4.928, 95%CI:1.233-19.696; P<0.05) and treatments after recurrence (RR=21.069, 95%CI:3.529-125.806; P<0.05) were the independent influencing factors for postoperative overall survival. Treatments to prevent recurrence was the independent influencing factor for postoperative recurrence-free survival (RR=4.486, 95%CI: 1.807-11.138; P<0.05).

Conclusions

Surgical treatments has certain clinical application value for HCC complicated with PVTT. PVTT staging, surgical procedure and treatments after recurrence are the independent influencing factors for postoperative overall survival. And treatments to prevent recurrence is the independent influencing factor for postoperative recurrence-free survival.

Key words: Carcinoma, hepatocellular, Neoplastic cells, circulating, Hepatectomy, Survival rate
表1 肝癌合并门静脉癌栓患者手术治疗后总体生存率的单因素分析
参数 例数 总体生存率（%） χ 2值 P值 无复发生存在率（%） χ 2值 P值
1年 2年 3年 1年 2年 3年
AFP（μg/L） ? ? ? ? 0.072 0.788 ? ? ? 3.206 0.073
? < 400 11 63.6 43.6 32.7 ? ? 54.5 43.6 21.8 ? ?
? ≥400 21 57.1 38.1 33.3 ? ? 57.1 38.1 23.8 ? ?
肿瘤数量 ? ? ? ? 5.887 0.015 ? ? ? 4.619 0.032
? 单发 27 66.7 47.9 39.9 ? ? 40.7 21.6 13.0 ? ?
? 多发 5 20.0 20.0 20.0 ? ? 20.0 20.0 20.0 ? ?
肿瘤直径（cm） ? ? ? ? 0.330 0.566 ? ? ? 0.024 0.877
? < 5 5 60.0 40.0 0.0 ? ? 40.0 0 0 ? ?
? ≥5 27 59.3 44.4 37.0 ? ? 33.3 18.5 11.1 ? ?
肿瘤包膜 ? ? ? ? 1.126 0.289 ? ? ? 2.355 0.125
? 有 1 - - - ? ? - - - ? ?
? 无 31 61.3 41.7 31.3 ? ? 35.5 15.5 7.7 ? ?
卫星灶 ? ? ? ? 1.534 0.215 ? ? ? 0.093 0.761
? 有 19 63.2 47.4 42.1 ? ? 36.8 21.1 10.5 ? ?
? 无 13 53.8 28.8 19.2 ? ? 30.8 15.4 15.4 ? ?
微血管侵犯 ? ? ? ? 0.014 0.907 ? ? ? 0.360 0.548
? 有 28 60.7 42.6 34.8 ? ? 35.7 17.1 8.6 ? ?
? 无 4 50.0 25.0 25.0 ? ? 25.0 25.0 25.0 ? ?
肿瘤病理分级 ? ? ? ? 1.657 0.647 ? ? ? 3.545 0.315
? 高分化 2 100.0 100.0 50.0 ? ? 50.0 50.0 50.0 ? ?
? 中分化 14 64.3 42.9 42.9 ? ? 42.9 21.4 14.3 ? ?
? 中-低分化 11 45.5 24.2 24.2 ? ? 27.3 0 0 ? ?
? 低分化 5 40.0 20.0 20.0 ? ? 20.0 20.0 20.0 ? ?
癌栓分级 ? ? ? ? 6.412 0.041 ? ? ? 4.938 0.085
? Ⅰ型 18 66.7 55.0 48.9 ? ? 38.9 27.8 13.9 ? ?
? Ⅱ型 11 45.5 9.1 9.1 ? ? 27.3 9.0 0 ? ?
? Ⅲ型 3 33.0 33.0 33.0 ? ? 33.0 33.0 33.0 ? ?
手术方式 ? ? ? ? 6.315 0.044 ? ? ? 3.566 0.059
? 肿瘤+癌栓整块切除 24 70.8 45.5 40.9 ? ? 45.8 20.0 10.0 ? ?
? 肿瘤切除+癌栓取出 8 25.0 25.0 12.5 ? ? 12.5 12.5 12.5 ? ?
复发后措施 ? ? ? ? 14.913 0.000 ? ? ? - -
? 有 18 72.0 55.6 38.9 ? ? - - - ? ?
? 无 10 20.0 0 0 ? ? - - - ? ?
预防复发措施 ? ? ? ? 14.913 0.000 ? ? ? 16.411 0.000
? 有 20 - - - ? ? 50.0 29.2 17.5 ? ?
? 无 12 - - - ? ? 8.3 0 0 ? ?
[1]
Guglielmi A, Ruzzenente A, Conci S, et al. Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations[J]. World J Gastroenterol, 2014, 20(24):7525-7533.
[2]
Li C, Zhao H, Zhao J, et al. Prognosis of patients with hepatocellular carcinoma and hypersplenism after surgery: a single-center experience from the People's Republic of China[J]. Onco Targets Ther, 2014(7): 957-964.
[3]
Kuo YH, Lu SN, Chen CL, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis[J]. Eur J Cancer, 2010, 46(4): 744-751.
[4]
Xu JF, Liu XY, Wang S, et al. Surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus: a novel classification[J]. World J Surg Oncol, 2015(13):86.
[5]
Liu PH, Lee YH, Hsia CY, et al. Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis[J]. Ann Surg Oncol, 2014, 21(6): 1825-1833.
[6]
Chok KS, Cheung TT, Chan SC, et al. Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis[J]. World J Surg, 2014, 38(2): 490-496.
[7]
Li H, Li B, Wei Y. Hepatocellular carcinoma patients with left portal vein tumor thrombus may benefit from left hemi-hepatectomy with caudate lobectomy[J]. Hepatogastroenterology, 2013, 60(126):1451-1455.
[8]
Tang QH, Li AJ, Yang GM, et al. Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study[J]. World J Surg, 2013, 37(6):1362-1370.
[9]
Kashiwazaki M, Hama N, Takiuchi D, et al. Resection and postoperative multidisciplinary treatment for hepatocellular carcinoma with massive portal venous tumor thrombus-a single-center experience[J]. Gan To Kagaku Ryoho, 2013, 40(12):1675-1677.
[10]
Peng ZW, Guo RP, Zhang YJ, et al. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Cancer, 2012, 118(19):4725-4736.
[11]
Zhou Q, Wang Y, Zhou X, et al. Prognostic analysis for treatment modalities in hepatocellular carcinomas with portal vein tumor thrombi[J]. Asian Pac J Cancer Prev, 2011, 12(11):2847-2850.
[12]
吴志军，蔡晶，徐爱兵，等．三维适形放疗联合肝动脉化疗栓塞治疗肝癌伴门脉癌栓的临床观察 [J]．中华医学杂志，2011, 91(40):2841-2844.
[13]
Shi J, Lai EC, Li N, et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2010, 17(8): 2073-2080.
[14]
Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J]. Radiology, 2011, 258(2): 627-634.
[15]
Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study[J]. Ann Surg Oncol, 2011, 18(2): 413-420.
[16]
Han K, Kim JH, Ko GY, et al. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: a comprehensive review[J]. World J Gastroenterol, 2016, 22(1): 407-416.
[17]
Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial[J]. J Hepatol, 2012, 57(4): 821-829.
[18]
Yu JI, Park HC, Lim do H, et al. Prognostic index for portal vein tumor thrombosis in patients with hepatocellular carcinoma treated with radiation therapy[J]. J Korean Med Sci, 2011, 26(8):1014-1022.
[19]
Xiao CZ, Wei W, Guo ZX, et al. A prognosis model for patients with hepatocellular carcinoma and portal vein tumor thrombus following hepatic resection[J]. Oncol Lett, 2015, 10(5): 2787-2794.
[20]
Yamamoto Y, Ikoma H, Morimura R, et al. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. World J Gastroenterol, 2015, 21(1): 246-253.
[21]
Ye JZ, Zhang YQ, Ye HH, et al. Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus[J]. World J Gastroenterol, 2014, 20(45):17141-17147.
[22]
Shaohua L, Qiaoxuan W, Peng S, et al. Surgical strategy for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis[J]. PLoS One, 2015, 10(6):e0130021.
[1] 钟锴, 蒋铁民, 张瑞青, 吐尔干艾力·阿吉, 邵英梅, 郭强. 加速康复外科在肝囊型棘球蚴病肝切除术中的应用分析[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 425-429.
[2] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 冯旺, 马振中, 汤林花. CT扫描三维重建在肝内胆管细胞癌腹腔镜肝切除术中的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 104-107.
[5] 赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[6] 唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[7] 杭轶, 杨小勇, 李文美, 薛磊. 可控性低中心静脉压技术在肝切除术中应用的最适中心静脉压[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 813-817.
[8] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[9] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[10] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[11] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[12] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[13] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[14] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[15] 吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？